OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon
Julie Zhou, Vicente E. Torres
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 245-260
Closed Access | Times Cited: 7
Julie Zhou, Vicente E. Torres
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 245-260
Closed Access | Times Cited: 7
Showing 7 citing articles:
Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease
Hüseyin Gül, Jamie A. Davies
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Hüseyin Gül, Jamie A. Davies
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Primary cilia and actin regulatory pathways in renal ciliopathies
Rita K. Kalot, Zachary T Sentell, Thomas M. Kitzler, et al.
Frontiers in Nephrology (2024) Vol. 3
Open Access | Times Cited: 4
Rita K. Kalot, Zachary T Sentell, Thomas M. Kitzler, et al.
Frontiers in Nephrology (2024) Vol. 3
Open Access | Times Cited: 4
Advancing Therapeutic Approaches and Shaping Future Perspectives in the Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Insights from Clinical Trials
Murali Krishna Moka, Deepalaxmi Rathakrishnan, S. K., et al.
European Journal of Pharmacology (2025), pp. 177634-177634
Closed Access
Murali Krishna Moka, Deepalaxmi Rathakrishnan, S. K., et al.
European Journal of Pharmacology (2025), pp. 177634-177634
Closed Access
Molecular Diagnosis and Identification of Novel Pathogenic Variants in a Large Cohort of Italian Patients Affected by Polycystic Kidney Diseases
Ersilia Nigro, Maria Amicone, Daniela D’Arco, et al.
Genes (2023) Vol. 14, Iss. 6, pp. 1236-1236
Open Access | Times Cited: 4
Ersilia Nigro, Maria Amicone, Daniela D’Arco, et al.
Genes (2023) Vol. 14, Iss. 6, pp. 1236-1236
Open Access | Times Cited: 4
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease
Philip W. Brownjohn, Azedine Zoufir, Daniel J. O’Donovan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Philip W. Brownjohn, Azedine Zoufir, Daniel J. O’Donovan, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Folate conjugated nanomedicines for selective inhibition of mTOR signaling in polycystic kidneys at clinically relevant doses
Rajasekharreddy Pala, Ayan Kumar Barui, Ashraf M. Mohieldin, et al.
Biomaterials (2023) Vol. 302, pp. 122329-122329
Open Access | Times Cited: 3
Rajasekharreddy Pala, Ayan Kumar Barui, Ashraf M. Mohieldin, et al.
Biomaterials (2023) Vol. 302, pp. 122329-122329
Open Access | Times Cited: 3
Editorial: Molecular mechanisms underlying polycystic kidney disease: from the smallest bricks to the big scenario
Annarita Di Mise, Michael J. Caplan, Giovanna Valenti
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access
Annarita Di Mise, Michael J. Caplan, Giovanna Valenti
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access
Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
Yeonsoon Jung, Yun Kyu Oh
Kosin Medical Journal (2023) Vol. 38, Iss. 2, pp. 87-97
Open Access | Times Cited: 1
Yeonsoon Jung, Yun Kyu Oh
Kosin Medical Journal (2023) Vol. 38, Iss. 2, pp. 87-97
Open Access | Times Cited: 1
